MONTREAL, April 3, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D infection, today announced that the European Association for the Study of the Liver (EASL) selection committee has accepted five Replicor abstracts for presentation at the EASL 2017 annual meeting to be held April 19-23, 2017 in Amsterdam, The Netherlands.
Four poster presentations will disclose new clinical and mechanistic data on the activity of NAPs against chronic hepatitis B infection:
- Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve Caucasian patients with chronic HBeAg negative HBV infection (Poster THU-154). This poster will also include new analysis of HBV RNA and HBcrAg dynamics during NAP-based combination therapy in the REP 401 protocol.
- Post-entry antiviral effects of nucleic acid polymers against HBV infection in vitro (Poster THU-156).
- Absence of mutations in the HBsAg “a” determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol (Poster THU-155).
- Nucleic acid polymer REP2139 monotherapy reveals a short half-life of serum HBsAg in HBeAg+ chronically infected HBV patients (Poster THU-173).
A fifth late breaking poster presentation will include 1 year post-treatment follow-up and new analysis of HBV RNA and HBcrAg dynamics during NAP-based combination therapy in patients with chronic hepatitis B / hepatitis D co-infection:
- One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection (Poster LBP-507).
Replicor’s presentations will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations. For the 2017 EASL Meeting: https://ilc-congress.eu/.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com